Snowden Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Snowden Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-17	Closed	–	–	1813
2021 Q4	$0	Buy	+17	New	+$651	﹤0.01%	2125

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Snowden Capital Advisors's PTCT Position: Q1 2022 in Review

Snowden Capital Advisors sold out of PTC Therapeutics (PTCT) in Q1 2022, closing a stake of 17 shares.

Snowden Capital Advisors first reported a position in PTCT in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 183 funds tracked by Wall St. Rank hold PTCT as of Q1 2022.

Snowden Capital Advisors reported no remaining PTC Therapeutics position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 17 PTC Therapeutics shares in Q1 2022.
Snowden Capital Advisors first reported a position in PTC Therapeutics in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's PTC Therapeutics position peaked at $0 in Q4 2021.
183 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.